Search
Filanesib
go.drugbank.com/drugs/DB06040InvestigationalFilanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Bacillus calmette-guerin substrain connaught live antigen
go.drugbank.com/drugs/DB10804ApprovedInvestigationalWithdrawnBacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Felypressin
go.drugbank.com/drugs/DB00093InvestigationalIt is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth … A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two
Fosinoprilat
go.drugbank.com/drugs/DB14207ExperimentalFosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.
Categories: Agents Acting on the Renin-Angiotensin SystemVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalA265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate
Mexiletine
go.drugbank.com/drugs/DB00379ApprovedInvestigationalAntiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Choline magnesium trisalicylate
go.drugbank.com/drugs/DB01401ApprovedCholine magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the f...